Cumberland Pharmaceuticals (NASDAQ: CPIX) to divest marketed brands to Apotex for $100M
Decision brief
Answer first · skim in under a minute
Structured plan for Cumberland Pharmaceuticals (NASDAQ: CPIX) to divest marketed brands to Apotex for $100M
Cumberland Pharmaceuticals (NASDAQ: CPIX) to divest marketed brands to Apotex for $100M is now closed: Form 8-K shows a July 1, 2026 cash close after June 24 shareholder approval, shifting CPIX toward retained ifetroban programs.
Contents10 sections
Key Takeaways
- Closing date: July 1, 2026; cash consideration: $100 million (Cumberland Form 8-K).
- Shareholder approval: special meeting June 24, 2026; definitive proxy filed May 26, 2026.
- Asset Purchase Agreement date: April 22, 2026 (Nuvo, Apotex, Cumberland).
- Transferred brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ; ifetroban retained.
What does the Cumberland 8-K say about the $100M sale?
Cumberland’s Form 8-K on the closing states that on July 1, 2026 it completed the sale of FDA-approved commercial assets to Nuvo Pharmaceuticals (Ireland) DAC and certain Apotex affiliates for $100 million cash.
The filing ties the close to shareholder approval at the June 24, 2026 special meeting. It also points to the definitive proxy statement filed May 26, 2026.
Which marketed brands moved to Apotex’s U.S. platform?
Per the 8-K, assets include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ, plus related equity interests.
Apotex’s July 1, 2026 PR Newswire release describes integrating Cumberland’s U.S. branded businesses into Apotex. It lists overlapping hospital and specialty brands.
- Agreement dated April 22, 2026.
- Buyers: Nuvo and Apotex affiliates.
- Seller: Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX).
- Structure: asset purchase, not a whole-company takeout.
What remains inside Cumberland after the divestiture?
The 8-K says Cumberland retained ifetroban product candidates and Cumberland Emerging Technologies, Inc. Management framed the company as continuing to develop those retained programs after shedding the commercial portfolio.
For BD models, treat post-close CPIX as a clinical-stage cash and pipeline story unless new branded products are licensed in.
How should analysts read the $100M number?
The $100 million figure is aggregate cash consideration at closing. Later filings may show purchase-price adjustments. It is not a valuation of the ifetroban pipeline.
Cross-check product identities on Drugs@FDA when mapping transferred NDAs to hospital channels Apotex will now detail.
What remains unproven after close?
Closing does not guarantee Apotex will grow each brand’s U.S. volume. It also does not prove ifetroban will reach approval.
Track subsequent 10-Q cash, any earnouts disclosed later, and ClinicalTrials.gov updates for retained candidates. Reconcile secondary brand lists against the 8-K asset list before they enter models.
How should desks update Cumberland Pharmaceuticals (NASDAQ: CPIX) notes?
Replace “pending shareholder vote” language with the July 1, 2026 close. Keep the April 22 agreement date and the June 24 vote date in the chronology. Mark marketed-brand revenue as discontinued operations for Apotex going forward.
Cumberland Pharmaceuticals (NASDAQ: CPIX) to divest marketed brands to Apotex for $100M is therefore a completed strategic pivot, not a proposed deal still awaiting a proxy vote.
For hospital channel forecasts, move Kristalose, Caldolor, Sancuso, Vibativ, Acetadote, and Vaprisol volume under Apotex’s U.S. branded operating assumptions after July 1, 2026. Keep any China or other territorial licenses that pre-date the deal on a separate line until the 8-K exhibits clarify assignment.
For pipeline desks, open a fresh ifetroban tracker. Do not assume the $100 million cash automatically funds a Phase 3 start; wait for the next earnings call or 10-Q use-of-proceeds language. That split—commercial brands gone, orphan-style pipeline retained—is the whole point of the April 22 Asset Purchase Agreement.
Also archive the May 26, 2026 DEFM14A filing date beside the June 24 vote and July 1 close. That three-date chain is what audit committees will ask for when they review how Cumberland Pharmaceuticals communicated the Apotex transaction to holders of CPIX common stock on Nasdaq. Keep the SEC 8-K URL in the same folder as the PR Newswire close notice so both sides of the deal stay citeable.
Related NovaPharma coverage
- Cumberland Pharmaceuticals company profile
- Apotex company profile
- Puma Biotechnology June 2026 update
Frequently Asked Questions
When did Cumberland close the Apotex brand sale?
Cumberland’s Form 8-K states the transaction closed on July 1, 2026 for $100 million in aggregate cash consideration after shareholders approved the deal at a June 24, 2026 special meeting.
Which products transferred to Apotex affiliates?
The 8-K lists FDA-approved products Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ, plus certain product-related equity interests, sold under an Asset Purchase Agreement dated April 22, 2026 among Nuvo Pharmaceuticals (Ireland) DAC, Apotex, and Cumberland.
What did Cumberland retain after the divestiture?
Cumberland retained assets tied to its ifetroban product candidates and Cumberland Emerging Technologies, Inc., which it said it intends to continue developing as a clinical-stage focus.
Primary Sources
Cumberland Pharmaceuticals pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
